Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: January 10, 2022
Reporting Period: Preliminary results for the fourth quarter and fiscal year ended January 2, 2022.
Context: The filing discloses a presentation made at the J.P. Morgan Healthcare Conference in San Francisco, California, regarding preliminary financial results.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached presentation transcript (Exhibit 99.1) and reconciliation exhibits (Exhibits 99.2 and 99.3), which are incorporated by reference but not detailed in the body of this 8-K.
Material Changes
No specific material changes versus the prior comparable period are quantified in the text of this filing. The document serves as a notification that preliminary results were presented and directs investors to the attached exhibits for detailed data.
Guidance, Outlook, and Management Commentary
- Management Commentary: Management presented preliminary financial results for Q4 and the full fiscal year 2022 at the J.P. Morgan Healthcare Conference.
- Guidance: The filing references a "Reconciliation of non-GAAP financial guidance for fiscal year 2022" as Exhibit 99.3, indicating that guidance was provided during the presentation, though specific targets are not listed in this text.
- Availability: The presentation transcript and webcast are available on the Company's Investor Relations website for at least 30 days.
Investor Verification Checklist
- Review Exhibit 99.1 (Transcript) for specific Q4 and full-year 2022 revenue and earnings figures.
- Examine Exhibit 99.2 for the reconciliation of preliminary non-GAAP operating margin for the fiscal year ended January 2, 2022.
- Consult Exhibit 99.3 for the specific non-GAAP financial guidance provided for fiscal year 2022.
- Verify the webcast recording on the Illumina Investor Relations website for management's qualitative commentary on market conditions.